Zevra Therapeutics (ZVRA) Competitors $10.46 +0.27 (+2.65%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. ANIP, OCUL, VERA, TWST, APGE, ABCL, DYN, IMCR, TLRY, and HROWShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include ANI Pharmaceuticals (ANIP), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), Twist Bioscience (TWST), Apogee Therapeutics (APGE), AbCellera Biologics (ABCL), Dyne Therapeutics (DYN), Immunocore (IMCR), Tilray Brands (TLRY), and Harrow (HROW). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors ANI Pharmaceuticals Ocular Therapeutix Vera Therapeutics Twist Bioscience Apogee Therapeutics AbCellera Biologics Dyne Therapeutics Immunocore Tilray Brands Harrow ANI Pharmaceuticals (NASDAQ:ANIP) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations. Which has more risk and volatility, ANIP or ZVRA? ANI Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Does the media prefer ANIP or ZVRA? In the previous week, Zevra Therapeutics had 2 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 4 mentions for Zevra Therapeutics and 2 mentions for ANI Pharmaceuticals. Zevra Therapeutics' average media sentiment score of 0.48 beat ANI Pharmaceuticals' score of 0.43 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zevra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ANIP or ZVRA? ANI Pharmaceuticals currently has a consensus price target of $97.29, suggesting a potential upside of 6.38%. Zevra Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 129.45%. Given Zevra Therapeutics' higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANI Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00Zevra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Do institutionals & insiders have more ownership in ANIP or ZVRA? 76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 12.7% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher earnings & valuation, ANIP or ZVRA? ANI Pharmaceuticals has higher revenue and earnings than Zevra Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioANI Pharmaceuticals$614.38M3.23-$18.52M-$0.77-118.77Zevra Therapeutics$23.61M24.87-$105.51M-$0.21-49.81 Is ANIP or ZVRA more profitable? Zevra Therapeutics has a net margin of 4.33% compared to ANI Pharmaceuticals' net margin of -1.37%. ANI Pharmaceuticals' return on equity of 25.03% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ANI Pharmaceuticals-1.37% 25.03% 8.00% Zevra Therapeutics 4.33%-112.40%-37.67% SummaryANI Pharmaceuticals and Zevra Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$587.96M$2.66B$6.14B$10.62BDividend YieldN/A56.92%5.70%4.74%P/E Ratio-49.8823.7085.7227.34Price / Sales24.87790.70625.97140.04Price / CashN/A169.9037.7861.77Price / Book14.145.5213.166.75Net Income-$105.51M$32.78M$3.30B$276.40M7 Day Performance10.92%7.00%5.29%3.58%1 Month Performance25.57%13.99%10.04%10.11%1 Year Performance24.97%0.74%88.00%35.83% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.7186 of 5 stars$10.46+2.6%$24.00+129.4%+30.8%$587.96M$23.61M-49.8820ANIPANI Pharmaceuticals3.7471 of 5 stars$89.64+0.6%$97.29+8.5%+64.2%$1.93B$614.38M-116.41600Analyst DowngradeOCULOcular Therapeutix3.982 of 5 stars$11.41+3.2%$22.13+93.9%+21.5%$1.92B$56.66M-8.91230Analyst ForecastInsider TradeHigh Trading VolumeVERAVera Therapeutics2.7829 of 5 stars$30.14+3.3%$63.00+109.0%-23.0%$1.86BN/A-8.4240Positive NewsAnalyst ForecastTWSTTwist Bioscience3.7607 of 5 stars$31.07+1.3%$48.90+57.4%-26.2%$1.85B$312.97M-21.43990Analyst ForecastAPGEApogee Therapeutics3.2571 of 5 stars$39.88+0.7%$92.63+132.3%-28.1%$1.83BN/A-9.6691ABCLAbCellera Biologics2.6931 of 5 stars$5.90-1.3%$8.00+35.6%+119.4%$1.79B$28.83M-10.73500DYNDyne Therapeutics3.6833 of 5 stars$13.06+4.1%$34.07+160.8%-56.0%$1.79BN/A-3.38100IMCRImmunocore2.6552 of 5 stars$34.21-3.1%$56.89+66.3%+11.3%$1.78B$310.20M-85.53320Positive NewsTLRYTilray Brands2.0883 of 5 stars$1.62+0.6%$1.94+19.6%+3.6%$1.77B$210.48M-0.702,842Upcoming EarningsHROWHarrow2.9398 of 5 stars$45.43-4.8%$68.50+50.8%-17.3%$1.77B$199.61M-181.72180Gap Up Related Companies and Tools Related Companies ANI Pharmaceuticals Alternatives Ocular Therapeutix Alternatives Vera Therapeutics Alternatives Twist Bioscience Alternatives Apogee Therapeutics Alternatives AbCellera Biologics Alternatives Dyne Therapeutics Alternatives Immunocore Alternatives Tilray Brands Alternatives Harrow Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
